Humacyte (NASDAQ:HUMA) Price Target Raised to $17.00

Humacyte (NASDAQ:HUMA) had its price target upped by Benchmark from $15.00 to $17.00 in a research note released on Monday,Benzinga reports. Benchmark currently has a buy rating on the stock.

Other equities research analysts have also issued reports about the company. Cantor Fitzgerald restated an “overweight” rating and set a $13.00 price target on shares of Humacyte in a research note on Friday, September 20th. HC Wainwright restated a “buy” rating and issued a $15.00 price target (up previously from $12.00) on shares of Humacyte in a report on Friday, December 20th. Piper Sandler set a $6.00 price objective on shares of Humacyte and gave the stock a “neutral” rating in a research note on Friday, October 18th. EF Hutton Acquisition Co. I raised shares of Humacyte to a “strong-buy” rating in a research note on Monday, September 9th. Finally, TD Cowen reaffirmed a “buy” rating and set a $10.00 price target on shares of Humacyte in a research report on Friday, October 18th. One investment analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Humacyte has a consensus rating of “Buy” and an average target price of $13.71.

Humacyte Trading Down 3.0 %

HUMA stock opened at $4.51 on Monday. The company has a quick ratio of 1.10, a current ratio of 1.10 and a debt-to-equity ratio of 0.61. The company has a market cap of $567.62 million, a price-to-earnings ratio of -3.37 and a beta of 1.38. The business has a fifty day simple moving average of $4.78 and a 200-day simple moving average of $5.79. Humacyte has a 52 week low of $2.48 and a 52 week high of $9.97.

Insider Buying and Selling

In other Humacyte news, CEO Laura E. Niklason sold 261,369 shares of Humacyte stock in a transaction that occurred on Wednesday, November 20th. The stock was sold at an average price of $4.40, for a total transaction of $1,150,023.60. Following the sale, the chief executive officer now directly owns 1,730,884 shares in the company, valued at $7,615,889.60. The trade was a 13.12 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Brady W. Dougan sold 427,459 shares of the company’s stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $4.34, for a total value of $1,855,172.06. Following the completion of the transaction, the director now directly owns 1,992,253 shares in the company, valued at approximately $8,646,378.02. The trade was a 17.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 1,500,000 shares of company stock valued at $6,606,799 in the last quarter. Company insiders own 11.20% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. State Street Corp lifted its position in shares of Humacyte by 66.1% during the third quarter. State Street Corp now owns 4,764,155 shares of the company’s stock worth $25,917,000 after purchasing an additional 1,895,529 shares during the last quarter. Millennium Management LLC grew its position in shares of Humacyte by 504.3% in the 2nd quarter. Millennium Management LLC now owns 1,599,307 shares of the company’s stock worth $7,677,000 after acquiring an additional 1,334,641 shares in the last quarter. Renaissance Technologies LLC grew its position in shares of Humacyte by 693.0% in the 2nd quarter. Renaissance Technologies LLC now owns 600,300 shares of the company’s stock worth $2,881,000 after acquiring an additional 524,600 shares in the last quarter. Marshall Wace LLP increased its holdings in shares of Humacyte by 3,301.5% in the 2nd quarter. Marshall Wace LLP now owns 463,662 shares of the company’s stock valued at $2,226,000 after acquiring an additional 450,031 shares during the last quarter. Finally, Deerfield Management Company L.P. Series C acquired a new stake in shares of Humacyte during the 2nd quarter valued at approximately $1,550,000. 44.71% of the stock is owned by institutional investors and hedge funds.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.